EGFR and non-small cell lung carcinoma: Survivin-mediated signaling integrating EGFR/STAT5 also has not been studied in melanoma, but in A549 non-small cell lung cancer cells, drug inhibition studies decrease EGFR, JAK2, STAT3, and STAT5 activation, and also downregulated Bcl-2 and survivin preventing proliferation and promoting apoptosis [69].